Which has preferable earnings and valuation, AGEN or CRDF?

Agenus has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 3.31 $120K $2.58 3.24 Cardiff Oncology $590K 147.67 -$45.85M -$0.60 N/A

Is AGEN or CRDF more profitable?

Agenus has a net margin of 69.33% compared to Cardiff Oncology's net margin of -7,885.43%. Agenus' return on equity of -47.68% beat Cardiff Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Agenus 69.33% -47.68% 57.73% Cardiff Oncology -7,885.43% -103.10% -75.52%

Does the media prefer AGEN or CRDF?

In the previous week, Agenus had 8 more articles in the media than Cardiff Oncology. MarketBeat recorded 11 mentions for Agenus and 3 mentions for Cardiff Oncology. Agenus' average media sentiment score of 0.31 beat Cardiff Oncology's score of 0.20 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Cardiff Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CRDF or AGMB?

Cardiff Oncology has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiff Oncology $590K 147.67 -$45.85M -$0.60 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Does the media favor CRDF or AGMB?

In the previous week, AgomAb Therapeutics had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 6 mentions for AgomAb Therapeutics and 3 mentions for Cardiff Oncology. AgomAb Therapeutics' average media sentiment score of 0.37 beat Cardiff Oncology's score of 0.20 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRDF or RZLT?

In the previous week, Rezolute had 20 more articles in the media than Cardiff Oncology. MarketBeat recorded 23 mentions for Rezolute and 3 mentions for Cardiff Oncology. Rezolute's average media sentiment score of 0.41 beat Cardiff Oncology's score of 0.20 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRDF or CCCC?

In the previous week, Cardiff Oncology had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for Cardiff Oncology and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.30 beat Cardiff Oncology's score of 0.20 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cardiff Oncology (CRDF) Competitors

$1.12 -0.06 (-5.08%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.12 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Compare

CRDF vs. AGEN, AGMB, RZLT, CCCC, and CABA

Should you buy Cardiff Oncology stock or one of its competitors? Cardiff Oncology's main competitors and comparable companies include Agenus (AGEN), AgomAb Therapeutics (AGMB), Rezolute (RZLT), C4 Therapeutics (CCCC), and Cabaletta Bio (CABA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cardiff Oncology compare to Agenus?

Agenus (NASDAQ:AGEN) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Agenus currently has a consensus price target of $24.50, indicating a potential upside of 193.06%. Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 569.64%. Given Cardiff Oncology's higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Agenus has a net margin of 69.33% compared to Cardiff Oncology's net margin of -7,885.43%. Agenus' return on equity of -47.68% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

In the previous week, Agenus had 8 more articles in the media than Cardiff Oncology. MarketBeat recorded 11 mentions for Agenus and 3 mentions for Cardiff Oncology. Agenus' average media sentiment score of 0.31 beat Cardiff Oncology's score of 0.20 indicating that Agenus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Cardiff Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agenus has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	3.31	$120K	$2.58	3.24
Cardiff Oncology	$590K	147.67	-$45.85M	-$0.60	N/A

61.5% of Agenus shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 8.8% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Agenus has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Summary

Agenus beats Cardiff Oncology on 12 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to AgomAb Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

16.3% of Cardiff Oncology shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AgomAb Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. AgomAb Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
AgomAb Therapeutics	N/A	N/A	N/A

Cardiff Oncology currently has a consensus price target of $7.50, suggesting a potential upside of 569.64%. AgomAb Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 338.08%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, AgomAb Therapeutics had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 6 mentions for AgomAb Therapeutics and 3 mentions for Cardiff Oncology. AgomAb Therapeutics' average media sentiment score of 0.37 beat Cardiff Oncology's score of 0.20 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiff Oncology has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	147.67	-$45.85M	-$0.60	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

Summary

AgomAb Therapeutics beats Cardiff Oncology on 7 of the 12 factors compared between the two stocks.

How does Cardiff Oncology compare to Rezolute?

Cardiff Oncology (NASDAQ:CRDF) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

In the previous week, Rezolute had 20 more articles in the media than Cardiff Oncology. MarketBeat recorded 23 mentions for Rezolute and 3 mentions for Cardiff Oncology. Rezolute's average media sentiment score of 0.41 beat Cardiff Oncology's score of 0.20 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	1 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by insiders. Comparatively, 14.8% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cardiff Oncology has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	147.67	-$45.85M	-$0.60	N/A
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A

Cardiff Oncology has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Cardiff Oncology presently has a consensus price target of $7.50, indicating a potential upside of 569.64%. Rezolute has a consensus price target of $10.44, indicating a potential upside of 160.46%. Given Cardiff Oncology's higher probable upside, equities analysts plainly believe Cardiff Oncology is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Rezolute	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Rezolute has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Rezolute's return on equity of -62.99% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Rezolute	N/A	-62.99%	-57.94%

Summary

Rezolute beats Cardiff Oncology on 9 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to C4 Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Cardiff Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 3.07, meaning that its stock price is 207% more volatile than the broader market.

Cardiff Oncology presently has a consensus target price of $7.50, suggesting a potential upside of 569.64%. C4 Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 137.29%. Given Cardiff Oncology's higher probable upside, equities research analysts clearly believe Cardiff Oncology is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cardiff Oncology had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for Cardiff Oncology and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.30 beat Cardiff Oncology's score of 0.20 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

C4 Therapeutics has a net margin of -289.44% compared to Cardiff Oncology's net margin of -7,885.43%. C4 Therapeutics' return on equity of -45.45% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

Cardiff Oncology has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	147.67	-$45.85M	-$0.60	N/A
C4 Therapeutics	$35.95M	10.10	-$104.99M	-$1.00	N/A

Summary

Cardiff Oncology and C4 Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Cabaletta Bio?

Cardiff Oncology (NASDAQ:CRDF) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Cardiff Oncology had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 3 mentions for Cardiff Oncology and 0 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.34 beat Cardiff Oncology's score of 0.20 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiff Oncology	Neutral
Cabaletta Bio	Neutral

Cardiff Oncology has higher revenue and earnings than Cabaletta Bio. Cardiff Oncology is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	147.67	-$45.85M	-$0.60	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Cabaletta Bio has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Cardiff Oncology's return on equity of -103.10% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Cabaletta Bio	N/A	-128.27%	-95.47%

16.3% of Cardiff Oncology shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cardiff Oncology has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.48, meaning that its share price is 248% more volatile than the broader market.

Cardiff Oncology currently has a consensus target price of $7.50, suggesting a potential upside of 569.64%. Cabaletta Bio has a consensus target price of $15.33, suggesting a potential upside of 666.67%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Cardiff Oncology and Cabaletta Bio tied by winning 8 of the 16 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDF vs. The Competition

Export

Metric	Cardiff Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$87.13M	$3.86B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-1.87	13.06	275.67	26.04
Price / Sales	147.67	1,292.17	656.66	111.05
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.67	16.63	10.93	6.31
Net Income	-$45.85M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-9.68%	-2.99%	-2.00%	-1.66%
1 Month Performance	2.75%	-10.81%	-6.19%	-4.68%
1 Year Performance	-48.86%	19.19%	8.03%	1.57%

Cardiff Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDF Cardiff Oncology	1.8962 of 5 stars	$1.12 -5.1%	$7.50 +569.6%	-48.9%	$87.13M	$590K	N/A	31	News Coverage Gap Up
AGEN Agenus	3.1714 of 5 stars	$9.43 +10.4%	$24.50 +159.8%	+101.9%	$385.68M	$114.20M	3.66	81	News Coverage High Trading Volume
AGMB AgomAb Therapeutics	3.3581 of 5 stars	$10.21 -2.9%	$37.50 +267.3%	N/A	$380.85M	N/A	N/A	62	News Coverage
RZLT Rezolute	3.1917 of 5 stars	$4.18 +7.2%	$10.00 +139.2%	-55.9%	$377.22M	N/A	N/A	71	Analyst Upgrade Analyst Revision
CCCC C4 Therapeutics	1.4894 of 5 stars	$3.12 +4.7%	$7.00 +124.4%	+30.0%	$366.61M	$35.95M	N/A	104

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDF) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiff Oncology (CRDF) Competitors

CRDF vs. AGEN, AGMB, RZLT, CCCC, and CABA

How does Cardiff Oncology compare to Agenus?

Summary

How does Cardiff Oncology compare to AgomAb Therapeutics?

Summary

How does Cardiff Oncology compare to Rezolute?

Summary

How does Cardiff Oncology compare to C4 Therapeutics?

Summary

How does Cardiff Oncology compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiff Oncology (CRDF) Competitors

CRDF vs. AGEN, AGMB, RZLT, CCCC, and CABA

How does Cardiff Oncology compare to Agenus?

Do analysts rate AGEN or CRDF?

Is AGEN or CRDF more profitable?

Does the media prefer AGEN or CRDF?

Which has preferable earnings and valuation, AGEN or CRDF?

Do institutionals and insiders have more ownership in AGEN or CRDF?

Which has more risk & volatility, AGEN or CRDF?

Summary

How does Cardiff Oncology compare to AgomAb Therapeutics?

Do institutionals and insiders hold more shares of CRDF or AGMB?

Is CRDF or AGMB more profitable?

Do analysts rate CRDF or AGMB?

Does the media favor CRDF or AGMB?

Which has stronger earnings and valuation, CRDF or AGMB?

Summary

How does Cardiff Oncology compare to Rezolute?

Does the media prefer CRDF or RZLT?

Do insiders & institutionals have more ownership in CRDF or RZLT?

Which has higher earnings and valuation, CRDF or RZLT?

Which has more risk and volatility, CRDF or RZLT?

Do analysts recommend CRDF or RZLT?

Is CRDF or RZLT more profitable?

Summary

How does Cardiff Oncology compare to C4 Therapeutics?

Which has more volatility & risk, CRDF or CCCC?

Do analysts recommend CRDF or CCCC?

Do insiders & institutionals hold more shares of CRDF or CCCC?

Does the media refer more to CRDF or CCCC?

Is CRDF or CCCC more profitable?

Which has preferable earnings and valuation, CRDF or CCCC?

Summary

How does Cardiff Oncology compare to Cabaletta Bio?

Does the media refer more to CRDF or CABA?

Which has better earnings & valuation, CRDF or CABA?

Is CRDF or CABA more profitable?

Do institutionals & insiders hold more shares of CRDF or CABA?

Which has more risk & volatility, CRDF or CABA?

Do analysts prefer CRDF or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools